Evidence map›Paper›PMID 17311003›Full record

ArticleOncogene2007

Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes.

H B Fleisig, N I Orazio, H Liang, A F Tyler, H P Adams, M D Weitzman, L Nagarajan

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. GWAS in Mice Maps Susceptibility to HIV-Associated Nephropathy to theJournal of the American Society of Nephrology : JASN · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Recruitment of the oncoprotein v-ErbA to aggresomes.Molecular and cellular endocrinology · 2011
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

H B FleisigDepartment of Molecular Genetics, MD Anderson Cancer Center, Houston, TX 77030, USA.
N I Orazio
H Liang
A F Tyler
H P Adams
M D Weitzman
L Nagarajan
The University of Texas MD Anderson Cancer Center · USSalk Institute for Biological Studies · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Viral Modulation of Genetic StabilityR01CA097093 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI WEITZMAN, MATTHEW D. · 2003 to 2019
$5.2M
SSDP2 Gene Pathway in Myeloid NeoplasmsR01HL074449 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NAGARAJAN, LALITHA · 2003 to 2006
$1.3M
MOLECULAR BIOLOGY OF THE CELLT32CA064041 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SEFTON, BARTHOLOMEW M · 1995 to 2004
$487k
NCI NIH HHS CA16672NCI NIH HHS CA97093NCI NIH HHS T32 CA064041NHLBI NIH HHS HL074449
6 · The paper itself

Abstract

Sequence-specific single-stranded DNA-binding protein 2 (SSBP2) is a candidate tumor suppressor for human acute myelogenous leukemia (AML). Inducible expression of SSBP2 causes growth arrest and partial differentiation in AML cells. Here, we report that the adenoviral oncoprotein E1B55K directly binds to endogenous SSBP2 protein and sequesters it into juxtanuclear bodies in adenovirally transformed human embryonic kidney (HEK) 293 cells. Similarly, transient expression of E1B55K in IMR90 fibroblasts and HeLa cells result in the formation of juxtanuclear bodies containing SSBP2. When nuclear export of E1B55K is prevented, SSBP2 remains associated with E1B55K in nuclear foci. A requirement for intact microtubules to retain the integrity of the juxtanuclear bodies suggests them to be E1B55K containing aggresomes. The adenoviral E1B55K protein has been shown to localize to the Mre11 complex and p53 to aggresome structures; together with the viral E4orf6 protein, E1B55K recruits a cellular E3 ubiquitin ligase that induces degradation of Mre11 and p53. However, our present studies reveal that E1B55K does not degrade SSBP2. These data demonstrate that E1B55K targets the candidate leukemia suppressor SSBP2 and suggest that subverting its function may contribute to cell transformation by viral oncoproteins.

Indexed as

Acid Anhydride HydrolasesAcute DiseaseAdenovirus E1B ProteinsCell LineCell Line, TumorCell NucleusDNA-Binding ProteinsDNA Repair EnzymesGreen Fluorescent ProteinsHeLa CellsHumansImmunoblottingImmunoprecipitationInclusion BodiesLeukemia, MyeloidMicroscopy, ConfocalAcid Anhydride HydrolasesAdenovirus E1B ProteinsDNA-Binding ProteinsDNA Repair EnzymesGreen Fluorescent ProteinsMRE11 Homologue ProteinMRE11 protein, humanRAD50 protein, humanRecombinant Fusion ProteinsSSBP2 protein, human

Identifiers

PMID17311003
OpenAlexW1991418001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.